NCT04056130View on ClinicalTrials.gov

A Study of Single and Multiple Ascending Doses of KBL697 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 4, 2019

Primary Completion Date

December 23, 2019

Study Completion Date

January 7, 2020

Conditions
Atopic Dermatitis (AD)
Interventions
DRUG

KBL697

"Part A: 1 day 460mg/day of KBL697 or placebo~Route of Administration: Oral"

DRUG

KBL697

"Part A: 1 day 4,600mg/day of KBL697~Route of Administration: Oral"

DRUG

KBL697

"Part B: 14 days~Cohort MAD1:~460mg/day of KBL697~Route of Administration: Oral"

DRUG

KBL697

"Part B: 14 days~Cohort MAD2:~4,600mg/day of KBL697~Route of Administration: Oral"

Trial Locations (1)

3004

Nucleus Network, Melbourne

Sponsors

Lead Sponsor

KoBioLabs
All Listed Sponsors
collaborator

Novotech (Australia) Pty Limited

INDUSTRY

lead

KoBioLabs

INDUSTRY

NCT04056130 - A Study of Single and Multiple Ascending Doses of KBL697 in Healthy Subjects | Biotech Hunter | Biotech Hunter